Angiogenesis Template
Write in a clean editor, then format for Angiogenesis in one click — DocuGuru applies the official Springer Nature template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the Angiogenesis format
Angiogenesis is a peer-reviewed journal published by Springer Nature, covering Angiogenesis and VEGF in Cancer, Cancer, Hypoxia, and Metabolism, Cell Adhesion Molecules Research.
| Publisher | Springer Nature |
|---|---|
| Reference style | Numbered (Springer Basic) Numbered — [1], [2] in the text 1. Smith A, Jones B, Lee C (2023) A representative article title. Angiogenesis 12:45–58
Formats any DOI in Angiogenesis style. No sign-up. |
| Publishes research in | Angiogenesis and VEGF in Cancer Cancer, Hypoxia, and Metabolism Cell Adhesion Molecules Research Lymphatic System and Diseases Protease and Inhibitor Mechanisms |
| ISSN | 0969-6970 |
| Citation impact (2-yr) | 7.43 |
| h-index | 124 |
| i10-index | 1,015 |
| Total citations | 72,552 |
| Article processing charge | $4,890 |
| Top institutions publishing here | Harvard University |
| Journal website | link.springer.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in Angiogenesis per year
Citation impact of Angiogenesis by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in Angiogenesis
Pharmacological inhibition of VEGF-A has proven to be effective in inhibiting angiogenesis and vascular leak associated with cancers and various eye diseases. However, little information is currently available on the binding kinetics and relative biological activity of various VEGF inhibitors. Therefore, we have evaluated the binding kinetics of two anti-VEGF antibodies, ranibizumab and bevacizumab, and…
Tumours require a vascular supply to grow and can achieve this via the expression of pro-angiogenic growth factors, including members of the vascular endothelial growth factor (VEGF) family of ligands. Since one or more of the VEGF ligand family is overexpressed in most solid cancers, there was great optimism that inhibition of the VEGF pathway…